Replimune Surges 127% After FDA Advisory Panel Backs Oncolytic Virus Cancer Therapy

Replimune Group shares surged 127% after a Food and Drug Administration advisory panel voted to support the company's oncolytic virus immunotherapy, a decision that substantially increases the probability of full FDA approval and commercial launch for its lead oncology asset targeting advanced melanoma.

• Replimune (REPL) shares jumped 127% after the FDA advisory panel voted in favor of its RP1 oncolytic virus therapy, signaling strong likelihood of full approval
• An FDA advisory panel vote in favor of a new therapy precedes formal approval in the vast majority of cases, opening the path to commercialization
• RP1 (vusolimogene oderparepvec) uses a modified herpes virus to stimulate anti-tumor immune response in advanced melanoma, with a differentiated mechanism vs checkpoint inhibitors

The FDA advisory committee vote represents a pivotal milestone for Replimune, with the panel's endorsement of RP1 clearing the highest clinical credibility hurdle before formal FDA approval. Advisory committee favorable votes historically translate into full approvals at a very high rate, making the day's 127% surge reflective of a market rapidly repricing the company's commercial potential from clinical-stage uncertainty to near-launch visibility.

RP1's mechanism of action—deploying a modified herpes simplex virus to directly kill tumor cells while simultaneously stimulating systemic anti-tumor immunity—differentiates it from standard checkpoint inhibitors that have dominated oncology for a decade. This combination approach addresses a known limitation of checkpoint therapies: their effectiveness in patients with 'cold' tumors that don't respond to immune checkpoint blockade alone.

For market participants, the FDA advisory panel outcome transforms Replimune from a pure pipeline bet into a pre-commercial company with significantly reduced binary risk. The 127% single-session move reflects both the relief of clearing this regulatory hurdle and new institutional buying as risk-adjusted return profiles shift. Key risks now center on the formal approval timeline, commercial launch execution, and pricing strategy for a differentiated but competing therapy in an increasingly crowded oncology market.

Source: GuruFocus | 1 source